MODERN ASPECTS OF HUMAN PAPILLOMAVIRUS VACCINATION
https://doi.org/10.30895/2312-7821-2018-6-3-111-117
Abstract
Human papillomavirus refers to DNA-containing viruses and infects the skin and mucosal epithelium. One common way is to change the expression of cellular genes by integrating the viral genome into cellular DNA. The reason for the resistance of HPV infection is the presence of complex mechanisms of inhibiting the immune response of the macroorganism. An important infectious agent involved in carcinogenesis are human papillomavirus (HPV) viruses, which cause a significant part of oncological diseases. Viruses create the prerequisites for malignant cells by introducing an oncogene or blockade of suppressor proteins in cells to disrupt the regulation of cell division. Two proteins, E6 and E7, encoded by the DNA of the virus, play a leading role in this process. More than 100 different types of HPV have been identified, and approximately one- third of them infect epithelial cells in the genital tract. HPV is also the cause of carcinoma of the penis, vulva, anus and contribute to the occurrence of more than 40 % of oropharyngeal cancer. To date, the most effective way to combat HPV infection is immunoprophylaxis. To date, there are three commercially available HPV vaccines: Cervarix®, Gardasil®, Gardasil®9. These three vaccines effectively prevent HPV infections, causing the production of neutralizing antibodies that bind to viral particles and block their entry into host cells. However, these vaccines are not effective in eliminating pre-existing infections. Currently, there are no therapeutic vaccines against HPV, approved for use in humans. The review discusses the types of vaccines against HPV infection and the effectiveness of vaccination.
About the Authors
O. S. Alyautdina
Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
The clinic “Mediluks”
Russian Federation
Russian Federation
8-2 Trubetskaya str., Moscow 119991, Russia
Lebyazhy lane, 8/4, bld 2, Moscow, 119019, Russian Federation
Obstetrician-gynecologist, head of obstetric-gynecological service. Professor of the Department of Obstetrics and Gynecology № 1 of Sechenov University. PhD, DSc (Med)
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
Senior Analyst Department for Evaluation of MIBPs Side Effects of the DEMPS
References
1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer. 2002;2:342–50.
2. DiMaio D, Lai CC, Klein O. Virocrine transformation: the intersection between viral transforming proteins and cellular signal transduction pathways. Annual Review of Microbiology. 1998;52:397–421. Review.
3. Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Bréchot C, Paterlini-Bréchot P. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut. 2005;54(8):1162–8.
4. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. Journal of Clinical Microbiol. 2006;44(5):1755–62.
5. Parkin DM. The global health burden of infectionassociated cancers in the year 2002. International Journal of Cancer. 2006;118:3030–44.
6. Nasiel K, Roger V, Nasiell M. Behaviour of mild cervical dysplasia during longterm follow- up. Obstetrics and Gynecology. 1986;67:665–9.
7. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, et al. Immunological events in regressing genital warts. American Journal of Clinical Path. 1994;102:768–74.
8. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause ofinvasive cervical cancer worldwide. Journal of Path. 1999;9:12–9.
9. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England Journal of Medicine. 2009;348:518–27.
10. Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. National Vital Statistics Report. 2012;60:1–69.
11. Alberts B, Johnson A, Walter P, Lewis J, Raff M, Roberts K. Molecular biology of the cell. 5th ed., New York: Garland Science; 2008; Chapter 20; Cancer, pp. 1230–56.
12. zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. Virology. 2009;384:260–5.
13. Yang BH, et al. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109(3):418–24.
14. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89(2):213–28.
15. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.
16. Goodman MT, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 2008;68(21):8813–24.
17. Rosa MI, et al. Persistence and clearance of human papillomavirus infection: a prospective cohort study. Am J Obstet Gynecol. 2008;199(6):e1–617e7.
18. Аляутдина ОС, Синицына ОВ. Оптимизация диагностики рака шейки матки. Российский медицинский журнал. 2015;21(6):25–7. [Alyautdina OS, Sinitsina OV. The optimization of diagnostic of cervix cancer. Rossiiskii meditsinskii zyurnal = RMJ. 2015;21(6):25–7 (In Russ.)]
19. Alyautdina OS, Sinitsina OV. The HPV cervical infection and intraepithelial colorectal lesions in women. Androl Gynecol Curr Res. 2018. DOI: 10.4172/2327-4360-C1-009
20. Kirnbauer R, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992;89(24):12180–4.
21. Villa LL, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.
22. Hildesheim A, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53.
23. Hung C-F, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421–39.
24. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24:S11–S25.
25. Bruni L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health 2016;4(7):e453–e463.
26. Massad LS, et al. Incidence of cervical precancers among HIV-seropositive women. Am J Obstet Gynecol. 2015; 212(5):606.e1–606.e8.
27. Poljak M, Šterbenc A, Lunar MM. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV). Expert Rev. Anti-Infect Ther. 2017.
28. Rowhani-Rahbar A, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis. 2007;196(6):887–94.
29. Clifford GM, Tully S, Franceschi S. Carcinogenicity of human Papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer. Clin Infect Dis. 2017;64(9):1228–35.
30. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr Opin Immunol. 2011;23(2):252–7.
31. Lin K, et al. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc. 2010;109(1):4–24.
32. Morrow MP, Yan J, Sardesai NY. Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccin. 2013;12(3):271–83.
33. M. Šmídková, et al. Plant production of vaccine against HPV: a new perspectives. In: Human Papillomavirus and Related Diseases-From Bench to Bedside-A Clinical Perspective, InTech, 2012.
34. Vici P, et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccin. 2016;15(10):1327–36.
35. Yang A., et al. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):75.
36. Kim HJ. Current status and future prospects for human papillomavirus vaccines. Arch Pharm Res. 2017:1–14.
37. Su JH, et al. Immunotherapy for cervical cancer. BioDrugs. 2010;24(2):109–129.
38. Khong H, Overwijk WW. Adjuvants for peptidebased cancer vaccines. J Immunother. Cancer. 2016;4(1):56.
39. Журавлева ЕО, Вельц НЮ, Затолочина КЭ, Глаголев СВ, Поливанов ВА, Дармостукова МА и др. Анализ спонтанных сообщений о нежелательных реакциях, развившихся при применении лекарственных средств во время беременности. Безопасность и риск фармакотерапии. 2017;5(2):61–9. [Zhuravleva EO, Velts NYu, Zatolochina KE, Glagolev SV, Polivanov VA, Darmostukova MA, et al. Analysis of spontaneous reports of adverse reactions, developed in the use of drugs during pregnancy. Bezopasnost i risk farmakoterapii = Safety and Risk of Pharmacotherapy 2017;5(2):61–9 (In Russ.)]
40. Снегирева ИИ, Затолочина КЭ, Дармостукова МА, Аляутдин РН, Романов БК. Современные подходы к взаимозаменяемости вакцин. Ведомости Научного центра экспертизы средств медицинского применения. 2016;(4):3–8. [Snegireva II, Zatolochina KE, Darmostukova MA, Alyautdin RN, Romanov BK. Modern approaches to vaccines interchangeability. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2016;(4):3–8 (In Russ.)]
41. Kenter GG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47.
Review
For citations:
Alyautdina O.S., Darmostukova M.A. MODERN ASPECTS OF HUMAN PAPILLOMAVIRUS VACCINATION. Safety and Risk of Pharmacotherapy. 2018;6(3):111-117. (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-3-111-117
Views:
1392
Email this article 